PGL PHARMA
ActiveSummary
PGL PHARMA has been active since 2021 and the Belgian Official Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €226,332 and a net result of €47,372. Equity is growing by about 8.2% per year across the filed financial years. Its solvency ranks better than 24% of 3,821 sector peers (NACE 70, financial year 2025). The computed 12-month bankruptcy probability is 0.1% (very low).
Group and network
Holdings and subsidiaries
2 holdingsHoldings 2
Source for every holding own accounts 2025
- PHARMACIE DE BOIS DE BREUXsubsidiaryEquity €171,711Result €29,160100%
- PHARMACIE DU THIER-A-LIEGEsubsidiaryEquity €103,528Result €30,143100%
According to the 2025 annual accounts of PGL PHARMA and those of the other companies, the acts in the Belgian Official Gazette and the LEI register. Annual accounts state the shareholders that notified the company under article 7:225 of the Code of Companies and Associations and the parent companies that consolidate it. The register of ultimate beneficial owners (UBO) is not public: who ultimately stands behind a natural person or a foreign parent is not stated here. A company that does not include these statements in its annual accounts, or does not have to, is not listed.
Connections & network
The network starts from this company’s shareholders. What else they own or run appears here as nodes.